The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
Open accessAbstract
TGF-beta effects on angiogenesis, stroma formation, and immune function suggest its possible involvement in tumor progression. This hypothesis was tested using the 2G7 IgG2b, which neutralizes TGF-beta 1, -beta 2, and -beta 3, and the MDA-231 human breast cancer cell line. Inoculation of these cells in athymic mice decreases mouse spleen natural killer (NK) cell activity. Intraperitoneal injections of 2G7 starting 1 d after intraperitoneal inoculation of tumor cells suppressed intraabdominal tumor and lung metastases, whereas the nonneutralizing anti-TGF-beta 12H5 IgG2a had no effect. 2G7 transiently inhibited growth of established MDA-231 subcutaneous tumors. Histologically, both 2G7-treated and control tumors were identical. Intraperitoneal administration of 2G7 resulted in a marked increase in mouse spleen NK cell activity. 2G7 did not inhibit MDA-231 primary tumor or metastases formation, nor did it stimulate NK cell-mediated cytotoxicity in beige NK-deficient nude mice. Finally, serum-free conditioned medium from MDA-231 cells inhibited the NK cell activity of human blood lymphocytes. This inhibition was blocked by the neutralizing anti-TGF-beta 2G7 antibody but not by a nonspecific IgG2. These data support a possible role for tumor cell TGF-beta in the progression of mammary carcinomas by suppressing host immune surveillance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One class, exemplified by galunisertib (LY2157299; developed by Eli Lilly) as a well-studied therapeutic291,292 consists of small molecule inhibitors of TGF-β receptor kinases.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [291]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Roberts, A. B., Sporn, M. B., Assoian, R. K., Smith, J. M., Roche, N. S., Wakefield, L. M., Heine, U., Liotta, L. A., Falanga, V., & Kehrl, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4167 · Cited by 2,867
Kehrl, J. H., Wakefield, L. M., Roberts, A. B., Jakowlew, S. B., Álvarez‐Mon, M., Derynck, R., Sporn, M. B., & Fauci, A. S. (1986) · The Journal of Experimental Medicine · doi:10.1084/jem.163.5.1037 · Cited by 1,581
Knabbe, C., Lippman, M. E., Wakefield, L. M., Flanders, K. C., Kasid, A., Derynck, R., & Dickson, R. B. (1987) · Cell · doi:10.1016/0092-8674(87)90193-0 · Cited by 974
Roberts, A. B., Anzano, M. A., Lamb, L. C., Smith, J. M., & Sporn, M. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5339 · Cited by 919
The Transforming Growth Factor-βs
Roberts, A. B., & Sporn, M. B. (1991) · Springer eBooks · doi:10.1007/978-1-4612-3210-0_8 · Cited by 869
Deactivation of macrophages by transforming growth factor-β
Tsunawaki, S., Sporn, M. B., Ding, A. H., & Nathan, C. (1988) · Nature · doi:10.1038/334260a0 · Cited by 862
Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta.
Postlethwaite, A. E., Keski-Oja, J., Moses, H. L., & Kang, A. H. (1987) · The Journal of experimental medicine · doi:10.1084/jem.165.1.251 · Cited by 777
Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes.
Kehrl, J. H., Roberts, A. B., Wakefield, L. M., Jakowlew, S. B., Sporn, M. B., & Fauci, A. S. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.137.12.3855 · Cited by 759
Rook, A. H., Kehrl, J. H., Wakefield, L. M., Roberts, A. B., Sporn, M. B., Burlington, D. B., Lane, H. C., & Fauci, A. S. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.10.3916 · Cited by 570
Transforming growth factor production by chemically transformed cells.
Moses, H. L., Branum, E. L., Proper, J. A., & Robinson, R. A. (1981) · PubMed · Cited by 497
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–108 of 108
Aucagne, R., Droin, N., Paggetti, J., Lagrange, B., Largeot, A., Hammann, A., Bataille, A., Martin, L., Yan, K.-P., Fenaux, P., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45213 · Cited by 117
Suzuki, E., Kim, S., Cheung, H.-K., Corbley, M. J., Zhang, X., Sun, L., Shan, F., Singh, J., Lee, W.-C., Albelda, S. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2389 · Cited by 113
Laverty, H. G., Wakefield, L. M., Occleston, N. L., O’Kane, S., & Ferguson, M. W. J. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.07.002 · Cited by 110
Suzuki, E., Kapoor, V., Cheung, H.-K., Ling, L. E., DeLong, P. A., Kaiser, L. R., & Albelda, S. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0611 · Cited by 65
Biswas, T., Gu, X., Yang, J., Ellies, L. G., & Sun, L.-Z. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.12.018 · Cited by 52
Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment
Lappano, R., Todd, L. A., Stanic, M., Cai, Q., Maggiolini, M., Marincola, F., & Pietrobon, V. (2022) · Cancers · doi:10.3390/cancers14030539 · Cited by 32
Cowan (2001) · doi:10.1002/1097-0215(20010101)91:1
Self-citation
Metadata
- Authors
- Arteaga, C. L., Hurd, S. D., Winnier, A. R., Johnson, M. D., Fendly, B. M., & Forbes, J. T.
- Affiliations
- Vanderbilt University (US)
- ORCID
- Arteaga, C L
- Venue
- Journal of Clinical Investigation
- Published
- 1993-12-01
- Volume
- 92
- Issue
- 6
- Pages
- 2569-2576
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC288452
- OpenAlex
- W2146839556
- Cited by
- 359
- References
- 40
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 6 · 2023: 3 · 2022: 6 · 2021: 7 · 2020: 5 · 2019: 7 · 2018: 7 · 2017: 10 · 2016: 4 · 2015: 5 · 2014: 6 · 2013: 11 · 2012: 8
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- TGF-beta, anti-TGF-beta antibody, breast cancer, natural killer cells, tumor immunosuppression, tumor progression, metastasis, MDA-MB-231 cells, tumor microenvironment, host immune surveillance, tumor-host interaction
- MeSH terms
- Animals, Antibodies, Breast Neoplasms, Cell Division, Collagen, Cytotoxicity, Immunologic, Factor VIII, Female, Humans, Immunoglobulin G, Killer Cells, Natural, Lung Neoplasms, Mice, Nude, Neoplasm Metastasis, Neoplasm Transplantation, Neovascularization, Pathologic, Recombinant Proteins, Spleen, Transplantation, Heterologous, Tumor Cells, Cultured, Transforming Growth Factor beta, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
